StockWatch
·

CAMLIN FINE SCIENCES LTD. Q2 FY27 Results

CAMLINFINEQ2 FY27 Results
Filing
Result:Poor· Market: Crashed#One-off hit#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue491.465.5%6.9%
Total Income496.424.8%6.9%
Expenditure529.742.6%14.1%
PBT-35.254.7%13386.1%
Net Profit-29.7011.7%98.7%
OPM0.06%0.41pp7.21pp
NPM-5.98%0.47pp2.76pp
EPS-1.39186.9%548.4%
View full financials

Core segment EBITDA margin collapsed to 0.45% from 7.27% a year ago and adjusted loss widened ~86% YoY, with the key Aroma segment swinging to a loss, so this is clear sector deterioration despite modest revenue growth.

CAMLIN FINE SCIENCES · Q2 FY27 · THE VERDICT

The ₹29.7 Crore Loss That Management Blames on Liquidity—But Fundamentals Tell Another Story

Reported loss of ₹29.7 crore masks a deeper operational collapse: vanillin volumes halved, the Aroma division posted an ₹11 crore loss, and every claim of EBITDA improvement contradicts the actual earnings. The company's ₹250 crore rights issue gamble is being sold as the cure, but the underlying business is deteriorating.

06 Nov 2026 · 6 min read
Reported PAT

-₹29.7 Cr

-98.7% YoY; NPM -6.0%

Claimed adjusted EBITDA

~8.0%

contradicted by -6% NPM + ₹163M interest burden

Revenue

₹491.5 Cr

+6.9% YoY, -5.5% QoQ

FY27 guidance (implied)

<₹600 Cr

vs. prior ₹2,200–2,300 Cr: 75% miss

On the surface, ₹491.5 crore revenue with a 6.9% year-on-year uptick looks defensible. But the quarter-on-quarter decline of 5.5%, combined with a reported net loss of ₹29.7 crore (NPM -6.0%), exposes what management calls a "liquidity crisis." Every claim of operational improvement—EBITDA margins of 8%, blends resilience, vanillin realization at $12—crumbles when tested against the actual profit line. The company is placing its entire survival bet on a ₹250 crore rights issue, with all improvement claims contingent on that capital closing and tariff regimes staying intact. The fundamentals suggest both bets are at risk.

The math that doesn't hold up

Management opened the call claiming an EBITDA margin of 8.04% improvement—a figure directly contradicted by the reported -6.0% net profit margin. With an operating profit of just ₹0.5 crore (0.1% OPM) on ₹491.5 crore revenue, and quarterly interest costs of ₹163 crore, there is no path to an 8% EBITDA margin. Depreciation and the interest burden consume the entire operating profit and then some. Management later conceded this was an "adjusted" figure contingent on liquidity—a claim unsupported by any restatement of the reported numbers. The actual EBITDA implied by the financials is closer to 2.5%.

With liquidity support, we can cross INR 6,000 million (₹600 Cr) turnover and EBITDA at 10%-odd in Q4.
Management's claims on the call: what holds up and what doesn't

EBITDA margin improved to 8.04% in Q2

Contradicted

Reported NPM -6.0%; operating profit ₹0.5 Cr on ₹491.5 Cr = 0.1% OPM. Interest burden ₹163M makes claimed 8% EBITDA implausible.

Vanillin production targeting 3,000 tons annual

Contradicted

Q2 sold only 358 metric tons ethyl vanillin vs. prior Q1 580 combined; implies ~1,400 ton annual run rate, 53% below target.

Specialty ingredient business holding INR 2,970M

Contradicted

Aroma division collapsed from ₹774M (Q1) to ₹472M (Q2); posted ₹11 Cr loss on 300 MT; net specialty business impaired.

Blends revenue back to INR 4,089M

Overstated

Total revenue ₹491.5 Cr; if blends alone ₹408.9 Cr, rest of business = ₹82.6 Cr—incoherent with stated volumes.

Able to hold blends market despite cost inflation

Partially true

Local competition reducing prices; cannot pass cost increases to end customers. Only blends have partial pricing power at 11–12% EBITDA margin; straights and Aroma cannot.

What changed on this call

Vanillin volumes halved. Q1 FY27 called for ~3,000 metric tons annual production as a pillar of the ₹2,200–2,300 crore FY27 revenue target. Q2 shipped only 358 MT. Management blamed distributor channel shifts (customers rerouting through Thailand/Malaysia to dodge US tariffs) and a May shift from methyl to ethyl vanillin that destroyed production continuity. Next guidance: 2.5–2.7k tons for the next calendar year—a further delay to the ramp. Aroma division moved to loss. Revenue collapsed from ₹774M (Q1) to ₹472M (Q2); the division posted a ₹11 crore loss on 300 MT, implying a -23% EBITDA margin due to unabsorbed fixed costs at low utilization. This was the quarter that killed confidence in the specialty ingredients turnaround narrative. FY27 total revenue guidance withdrawn. The prior ₹2,200–2,300 crore target was never formally retracted, but Q1+Q2 combined = ₹491.5 crore. For full-year guidance to hold, H2 would need ~₹1.7–1.8 lakh crore—arithmetically impossible. Implied FY27 total is now Diphenol plant shuttered indefinitely. The 18,000 MT capacity has been offline since May 2026 due to uneconomic phenol raw material costs (doubled globally due to Chinese capacity). Quarterly maintenance burn is ₹5 crore (down from ₹8–9 crore last quarter) with no restart plan. Management acknowledged Chinese competitors have "vastly lower cost structure"; pricing "way, way below our cost."

The street's own verdict: stock action and ownership flows

The stock trades at ₹76.13 as of 5 November 2026, down 77% from its all-time high and trading below all key moving averages (SMA20 ₹86.19, SMA50 ₹94.15, SMA200 ₹120.66). The drawdown is not a temporary dip—it is a structural repricing. Ownership tells the same story: FII holdings have evaporated to 0.91% (down from 2.88% in FY2025 Q1), while DII holdings fell to 5.42% from a prior 7.77%. Promoters remain at 48.03%, unchanged. Recent bulk activity shows JUNOMONETA FINSOL executing paired buy-sell orders at ₹119.80–119.87, suggesting internal rebalancing rather than external conviction. The market is voting with its feet: this is not a turnaround story the street believes in.

The bull-bear ledger
  • Blends EBITDA margin held at 11–12% despite raw-material inflation

  • US vanillin demand visibility 2.5–2.7k MT next calendar; Europe 1.3–1.5k MT

  • ₹250 crore rights issue approved by board; addresses working capital crisis if accepted by promoters

  • Reported loss of ₹29.7 crore on revenue of ₹491.5 Cr; NPM -6.0%

  • Claimed EBITDA margin of 8% directly contradicted by -6% NPM and ₹163M quarterly interest burden

  • Vanillin volumes sold Q2: 358 MT (vs. prior 3,000+ MT annual target; 88% miss)

  • Aroma division: ₹11 crore loss in one quarter; revenue collapsed 39% QoQ to ₹472M

  • Diphenol plant shuttered indefinitely; maintenance burn ₹5 crore quarterly with no restart plan

  • Prior FY27 guidance (₹2,200–2,300 Cr revenue) now implicitly <₹600 Cr; 75% miss

  • Vanillin realization at $12 net is temporary arbitrage; normalized realization $8–9 once tariff regime shifts

Risks, ranked by how much they should concern a holder

Vanillin tariff arbitrage is temporary; realization pressures when window closes

High

Current $12 realization relies on US tariff enforcement and distributor rerouting through Thailand/Malaysia. Once legal risk recedes or tariff regime shifts (12–18 months estimated), realization compresses to $8–9, shrinking blends margin from 11–12% to 8–9%. This is the core earnings assumption for FY28 recovery.

Rights issue pricing and acceptance; dilution risk

High

Company negotiating ₹250 crore rights issue at a moment of maximum leverage. If pricing is heavily dilutive or promoters reject it at offered terms, working capital remains a crisis constraint and growth will stall. No alternative funding source disclosed.

Aroma division structural impairment; further write-downs likely

High

Aroma posted ₹11 crore loss on 300 MT in Q2 after methyl-to-ethyl vanillin switch. Fixed cost absorption is failing at low utilization (39% QoQ revenue collapse). Division is now a cash drain; risk of further impairment or exit decision.

Diphenol plant competitive death; maintenance burn ongoing

High

Chinese capacity and raw material positioning are vastly superior; pricing "way, way below our cost." Quarterly maintenance burn ₹5 crore (target ₹2.5 crore Q4) is recurrent with no restart plan. Risk of eventual write-down or forced divestiture.

Working capital crisis unresolved if rights issue fails or pricing unacceptable

High

Accounts payable aged 90+ days; working capital at only 60 days vs. normal 200 days. Channel financing used to fund operations; interest cost ₹163M monthly. If liquidity is not restored, growth and margin recovery are impossible.

Cost pass-through failure in straights and Aroma

Medium

Local competition reducing prices; management unable to pass raw-material cost inflation to end customers. Blends have partial pricing power (11–12% EBITDA), but straights and Aroma are structurally vulnerable to margin compression.

Management credibility erosion; prior guidance 75% miss

Medium

FY27 revenue guidance of ₹2,200–2,300 crore is unachievable at current trajectory (Q1+Q2 = ₹491.5 Cr); never formally withdrawn. Management's Q3–Q4 improvement claims rest on unproven execution and external factors (tariff, liquidity).

What to watch next
  • 1 · Rights issue pricing and closure (Nov–Dec 2026)

    This is the gate for all H2 recovery claims. If pricing is >50% dilutive or promoter acceptance stalls, the "with liquidity" narrative collapses and Q3 will show no improvement. Watch the announcement carefully; discount all management commentary on margin recovery unless capital actually closes.

  • 2 · Vanillin realization and Q3 volumes (announcement in late Jan 2027)

    Management claims $12 net realization will hold through Q3; but with tariff enforcement uncertainty and Chinese rerouting now facing legal risk, watch whether realization drops below $11. Volumes must show sequential improvement from 358 MT (Q2); anything flat or down is a red flag for the CY27 guidance.

  • 3 · Aroma stabilization or exit signal (Q3 earnings)

    The division is on life support after the ₹11 crore Q2 loss. Q3 must show at least a break-even result or material volume uptick; if losses continue or revenue remains <₹500M, expect an exit/divestiture announcement in Q4 or early FY28.

This is a step-change deterioration, not a steady-state operational miss. The company went from ₹2,200–2,300 crore FY27 guidance to sub-₹600 crore implied reality; from vanillin as a growth pillar to 88% volume miss; from specialty ingredients upside to ₹11 crore divisional losses. Management's "with liquidity" narrative is a survival posture dressed as a recovery story. Every improvement claim is external (tariff holds, rights issue prices, distributor demand ramps)—nothing has been earned operationally.

The single number to track from here is the actual EBITDA margin realized post-rights-issue closing. Not the claimed 8–10%, but the actual margin implied by the P&L. If Q3 or Q4 shows organic EBITDA margin above 5%, the bear case weakens. If it stays at 2–3%, the company remains in a liquidity trap with no exit without continued external support. Given prior guidance credibility destruction and structural headwinds (Aroma loss, diphenol death, tariff arbitrage temporary), the burden of proof is on management—and so far, this quarter did not deliver it.

Informational and educational content only. Not investment advice.